The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors.
Shubham Pant
Honoraria - Novartis
Lowell L. Hart
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Jeffrey R. Infante
No relevant relationships to disclose
Suzanne Fields Jones
No relevant relationships to disclose
Adil Mohyuddin
No relevant relationships to disclose
Patrick Murphy
No relevant relationships to disclose
Jeffrey Patton
Employment or Leadership Position - Tennessee Oncology
Stock Ownership - Raintree oncology services
Honoraria - Varian Medical Systems
William Charles Penley
No relevant relationships to disclose
Dana Shelton Thompson
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose